DYRK1A and Alzheimer disease: To determine the effects of chronic inhibition of Dyrk1 on AD‐like pathology, we treated 10‐month‐old female 3xTg‐AD (n = 13) and NonTg (n = 15) mice with a Dyrk1 inhibitor (Dyrk1‐inh), which was delivered via daily intraperitoneal (i.p.)injections for eight weeks (12.5 mg kg−1).